Notch signalling in cancer stem cells by Bolós Fernández, Victoria et al.
Clinical and Translational Oncology. 2009; 11(1): 11-19 
Notch signalling in cancer stem cells 
Victoria Bolós
1
, Moisés Blanco
2
, Vanessa Medina
2,3
, Guadalupe Aparicio
3
, Silvia Díaz-Prado
2,4
, 
Enrique Grande
1
 
1. Medical Oncology Department, Pfizer Spain, Alcobendas, Madrid, Spain 
2. Institute for Biomedical Research (INIBIC), A Coruña University Hospital, A Coruña, Spain 
3. Oncology Research Unit, A Coruña University Hospital, A Coruña, Spain 
4. Medicine DepartmentUniversity of A Coruña, A Coruña, Spain 
Abstract 
A new theory about the development of solid tumours is emerging from the idea that solid tumours, like 
normal adult tissues, contain stem cells (called cancer stem cells) and arise from them. Genetic mutations 
encoding for proteins involved in critical signalling pathways for stem cells such as BMP, Notch, Hedgehog 
and Wnt would allow stem cells to undergo uncontrolled proliferation and form tumours. Taking into account 
that cancer stem cells (CSCs) would represent the real driving force behind tumour growth and that they may 
be drug resistant, new agents that target the above signalling pathways could be more effective than current 
anti-solid tumour therapies. In the present paper we will review the molecular basis of the Notch signalling 
pathway. Additionally, we will pay attention to their role in adult stem cell self-renewal, and cell fate 
specification and differentiation, and we will also review evidence that supports their implication in cancer. 
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Introduction 
Notch signalling is a developmental conserved signalling pathway that plays a fundamental 
role in embryonic development and adulthood. During embryonic development, Notch activation 
allows definition of the cell fate of groups of embryonic stem cells. The Notch pathway also has a 
critical role in the self-renewal of adult tissues due to its involvement in the differentiation of non 
differentiated somatic stem cell populations into specific cell types.  
 
The Notch pathway uses both membrane-bound ligands and receptors. This fact makes 
fundamental the existence of intercellular contact for the signal transmission. 
 
Notch is a large membrane protein that is expressed in signal-receiving cells and, therefore, it 
works as a receptor. In mammals, there are four Notch receptors (Notch1–4) with a complex 
dimeric structure composed of transmembrane monomer bound through non-covalent interactions 
to a fully extracellular monomer. On the one hand, the intra-cellular face of the transmembrane 
monomer contains a number of important domains which are involved in the transduction and 
modulation of the signal. Immediately next to the membrane there is a RAM (RBPjk Associate 
Molecule) domain followed by a number of motifs name dAnkyrin repeats, which mediates the 
interaction with the Csl (CBF1 in mammals/Su(H) in Drosophila/Lag-1 in Caenorhabditis elegans) 
transcription factor. Additionally, there is a transactivation domain (TAD), two nuclear 
localisation signals (NLS) and a PEST region, which is the site for Notch ubiquitination. 
Therefore, the PEST domain negatively regulates protein stability. On the other hand, the 
extracellular face of the Notch transmembrane monomer shows a hydrophobic heterodimerisation 
region which mediates the binding to the Notch extracellular monomer (Fig. 1). 
 
 
 
Fig. 1. Notch signalling elements. NOTCH proteins are single-pass transmembrane receptors harbouring alarge 
extracellular domain involved in ligand binding and a cytoplasmic domain involved in signal transduction. The 
extracellular domain contains multiple EGF-like portions that are critical for ligand binding. The EGF-like portions are 
followed by a LIND domain (three cysteine-rich repeats) that prevents signalling in the absence of the signal. The 
intracellular domain is involved in protein–protein interactions and in the activation of the transcription. In fact, it contains 
a TAD and two NLS. The intracellular PEST sequence negatively regulates protein stability. Notch ligands are also bound 
to neighbouring cells. Ligands have an amino-terminal domain termed DSL (for Delta, Serrate and LAG-2 domain), 
followed by a different number of EGF-like portions. Adapted from [19] 
The extracellular Notch monomer is composed, in addition to the heterodimerisation region, of 
a number of cysteine-rich Lin12 repeats and, in the more distant zone, more than 36 epidermal 
growth factor (EGF)-like repeats that are critical for the interaction with the Notch 
ligand(fundamentally 11 and 12 EGF-like repeats).  
 
In mammals there are five conventional ligand molecules: three delta-like ligands (homologous 
to the delta ligand of Drosophila), Dll1, Dll3 and Dll4, and two jagged ligands (homologous to the 
serrate ligand of Drosophila), Jag1 and Jag2 (Fig. 1). Both families of ligand are also 
transmembrane proteins with a shorter intracellular face than Notch receptors. Jagged ligands 
display a cysteine-rich region followed by less EGF-like repeats than Notch and, finally, a DSL 
(Delta, Serrate and LAG2) domain. Al-though delta-like ligands contain the entire DSL region, 
they lack a cysteine-rich region and have less EGF-like re-peats than jagged ligands. DSL regions 
are functionally important because they are responsible for interacting with the 11 and 12 EGF-
like repeats of the Notch receptor. Additionally, the Notch EGF-like repeats 23–25 can also 
interact with delta-like ligands but not with the jagged ligands [1]. 
  
Currently, a new model of development of tumours is emerging and supports the idea that 
tumours, like normal adult tissues, arise from stem cells. In this model cancer stem cells (CSC) 
would be the real driving force behind tumour growth. CSCs would retain the differentiation 
potential giving rise to non-self-renewing differentiated tumour cells that would constitute the bulk 
of the tumour. It seems that genetic alterations in critical signalling pathways that govern stem 
cells such as Notch, Wnt, BMP (Bone Morphogenic Protein) and Hedgehog signalling pathways 
would allow stem cells to become independent of growth signals or resist antigrowth signals and 
would allow them to undergo uncontrolled proliferation and tumorigenesis[2]. As we will review 
below, a growing amount of evidence has already shown an association between alterations in the 
Notch signalling pathway and cancer, supporting the hypothesis mentioned above [3]. In fact, 
based on published reports that show the relationship of Notch signalling and cancer, clinical trails 
with Notch signalling inhibitors are underway in cancer patients.  
A walk along the Notch pathway 
A number of proteins participate in Notch-mediated signalling, some of them involved in 
Notch receptor processing [4]. Initially, Notch is synthesised as a large entire molecule that 
subsequently is cleaved in the Golgi by a furin-like convertase during the export process to the 
plasmatic membrane. Furthermore, Notch is also glycosylatedin the Golgi. The glycosylation 
profile seems to be critical for the binding of Notch to a specific ligand. In Drosophilatwo 
enzymes, O-fut1 (O-fucosyltransferase) and fringe (O-fucosylpeptide β-1,3-N-
acetylglucosaminyltransferase), are involved in Notch receptors and ligand glycosylation. 
Invertebrates this process is carried out by the O-fut1 homologue Pofut1 and by the fringe 
homologous Lunatic, Manic and Radical Fringe. 
 
The Notch canonical pathway starts when a transmembrane ligand (that belongs to the Delta-
like or Jagged family) in a signal-sending cell interacts with the Notch extra-cellular region of a 
signal-receiving neighbourhood cell[5]. Subsequently, the signal-sending cell, which expresses the 
ligand, cleaves the Notch extracellular domain that interacts with the ligand in the Notch S1 site 
and endocytes this ligand-receptor complex. The release of the Notch extracellular domain allows 
the exposition in the Notch trans-membrane domain of the signal-receiving cell of a site fora new 
cleavage (the S2 site) by a membrane metalloprotease belonging to the ADAM/TACE (desintegrin 
and metallopeptidase/tumour necrosis factor αconverting enzyme) family (Adam10 and Adam17 
in mammals). As a result of this cleavage, the transmembrane- intracellular segment of Notch is 
endocyted by the signal- receiving cell, which subsequently undergoes another cleavage in the 
receptor (in the S3 and S4 sites) by a γ- secretase complex (composed presently of 1 and 2, the 
catalytic components, and nicastrin, Aph1 and Pen2 in mammals). This cleavage leads to the final 
release of the cytoplasmatic intracellular active form of Notch, the Notch intracellular domain 
(NICD)(Fig. 2). 
 
Then, NICD translocates to the nucleus and binds to the transcription factor C-promoter 
binding factor 1 (Cbf1) that is the Csl transcription factor in mammals. This inter-action converts 
Cbf1 from a transcriptional repressor into a transcriptional activator of target genes by displacing 
nu-clear co-repressor and histone deacetylase complexes and recruiting nuclear co-activator 
proteins such as Mastermind(Fig. 2).  
 
In contrast, Notch signalling is switched off through the binding of Skip (Ski-Interacting 
Protein) protein to the Cbf1:NICD:Mastermind complex. Skip promotes the recruitment of 
kinases, which phosphorylate TAD and PEST domains of NICD. These phosphorylated sites are 
then recognised by specific ubiquitin ligases that trigger NICD destruction (Fig. 1). Finally, Cbf1 
returns to its initial state as a transcriptional repressor of target genes [1]. 
  
 
 
 
Fig. 2. Notch signalling pathway. Notch receptors are synthesised as single precursor proteins that are cleaved during 
transport to the cell surface, where they are expressed as heterodimers. Following the binding of the ligand, placed in the 
surface of a neighbouring cell, NOTCH is activated by two consecutive proteolytic cleavages that release its intracellular 
domain (NICD). The first proteolytic cleavage is mediated by the metalloprotease TACE, which cleaves the receptor on the 
extracellular side, near the transmembrane domain. The second cleavage occurs within the transmembrane domain and is 
mediated by a gamma-secretase activity whose key component is presenilin. This final cleavage liberates the NICD, which 
subsequently translocates to the nucleus where it binds to the transcription factor CBF1. This interaction converts CBF1 
from a transcriptional re-pressor into a transcriptional activator by displacing nuclear co-repressor proteins (CoR) and 
through the recruitment of nuclear co-activator proteins (CoA). Adapted from [19] 
Although most of the Notch cellular responses occur as a result of the activation of the 
canonical Notch pathway described above, there are other proteins that may also act as Notch 
ligands and trigger Notch activation. This non-canonical Notch pathway involves other 
transmembrane proteins with EGF-like repeats such as Dner, F3/Contactin1 and NB-3/Contactin 
6. However, these Notch ligands bind Notch receptors with less affinity than the convention-al 
Notch ligands (delta and Jagged) due to the lack of the DSL region [6]. 
 
Finally, Notch signalling may involve a number of other proteins such as CCN proteins, which 
are secreted to the extracellular environment where they may act as regulators of the Notch signal 
[7]. 
  
Notch signalling and trafficking: ligand and receptorendocytosis 
In several observations in Drosophila, it has been seen that the mutants with defects in the 
mechanisms of endocytosis and vesicular trafficking also display defects in Notch signalling. 
These findings suggest that endocytosis and cellular trafficking are necessary and are linked with 
Notch signalling [1]. 
 
On the one hand, once ligand-receptor interaction takes place, the first step for triggering 
Notch endocytosis/internalisation seems to be its mono-ubiquitination. Notch internalisation leads 
to the proteolytic cleavage of the receptor by the γ- secretase complex and the subsequent NICD 
release and translocation to the nucleus to regulate the expression of target genes. On the other 
hand, Notch ubiquitination and endocytosis, without previous interaction of Notch with a specific 
ligand, may give rise to two different responses: Notch degradation or Notch activation in a 
ligand-independent manner [8]. 
 
Three ubiquitin ligases that are able to trigger Notch endocytosis have been identified in 
Drosophila: Deltex(Dx), Nedd4 and Suppressor of Deltex (Su(Dx)). Deltex labels with ubiquitins 
the ankyrin-rich domain of Notch. Nedd4 and Su(Dx) label the HECT (homologous to E6-
APcarboxyl terminus) domain of Notch with ubiquitins. Al-though the role of Dx, Su(Dx) and 
Nedd4 is unclear, it is likely that they may regulate Notch signalling [8]. Since Dx seems to have a 
positive effect on Notch signalling activity, it seems that the Dx-mediated endocytosis of Notch 
avoids Notch degradation after its activation in a ligand-in-dependent manner. However, both 
Nedd4 and Su(Dx) have a negative effect on Notch signalling, leading the Notch-containing 
endocytic vesicles toward degradation.  
 
Furthermore, evidence suggests that ubiquitination and endocytosis of Notch ligands are also 
necessary for triggering Notch signalling. Ligand endocytosis after ligand-receptor interaction 
promotes the separation of Notch extracellular fragments (also endocyted by the ligand- 
expressing cells) and exposes specific sites in the transmembrane region of the receptor for 
cleavage by ADAM proteases. Additionally, it has also been suggested that ligand endocytosis 
leads to its post-translational modification. Therefore, it seems that after ligand endocytosis and 
modification, the modified ligand is competent to activate the signaling through its interaction with 
Notch and a subsequent ligand-receptor endocytosis [8]. Notch modification by the Pofut1 
fucosyltransferase also seems to be important for its endocytosis-dependent signalling [9]. 
Notch in action: normal functions, target genesand mechanisms of action 
Many of the cellular responses carried out by the Notch pathway have been discovered through 
the analysis of the phenotype derived from mutations in Drosophila Notch genes. These mutations 
mainly affect the development of the nervous and sensory organs.  
 
The main effectors of Notch activation that promote Notch-mediated cellular responses are 
transcription factors belonging to the basic helix-loop-helix (bHLH) family. In Drosophila, a gene 
known as Hairy and a gene cluster called Enhancer of split complex (E(spl)-C) are effectors of 
Notch activation taking part in the development of nervous components as well as in muscle and 
visceral development. In mammals the Hes (Hairy Enhancer of split) family, composed of seven 
genes (Hes1-7), is homologous to the Drosophila Hairy and E(spl)-C.Hes1plays an important role 
in nervous system and sensory organ development, as well as in the development of pancreas and 
other endocrine cells [10]. Hes1 and Hes7 are also involved in somitogenesis and, therefore, in the 
development of the body pattern [11]. Hey, also known as Hrt, Hesr, Herpor Chf, is a subfamily of 
Hairy and Enhancer of split related genes that is also involved in Notch response in vertebrates. 
This subfamily of genes is critical for the development of the cardiovascular system [10]. 
  
Notch is involved in cell fate decisions in embryonic and adult stem cells and progenitors. 
Notch is also involved in terminal differentiation events in specific tissues. Additionally, Notch 
promotes the development of new cell types at the boundaries of two distinct cell populations. 
Thus, there are several processes where Notch is involved. These processes affect the control of 
melanocyte generation and epidermal development [12, 13], cardiac and vascular sys-tem 
development [14–16], the development of haematopoietic cell lineage, gastric mucosa renewal and 
nervous sys-tem development [17]. Notch signalling has also been shown to be essential for proper 
prostate development in male mammals [18].  
 
Besides bHLH transcription factors, other genes have been identified as Notch targets and 
some of them are tissue specific. Among these genes are the protooncogene c-Myc, Skip2 and 
Deltex1 genes (both of which encode for proteins with ubiquitin ligase activity) and genes that 
encode for cell cycle regulators such as p27KIP1 and cyclin D1[19]. 
 
Notch is able to allocate the suitable fates to different cells. In this case Notch signal must be 
directed. Therefore, one cell must assume the role of signal-sending cell ex-pressing high levels of 
Notch ligands, whereas another neighbour cell may play the role of signal-receiving cell, and 
therefore this cell must express high levels of Notch receptors. However, neighbourhood cells 
usually express both ligands and receptors at the same level, making it impossible to distinguish 
the cell that sends the signal and the cell that receives it. There are several models to explain how 
the directionality in the signalling is achieved: the lateral inhibition model as well as asymmetric 
cell division and modulation of the activity of the ligands and the receptors [20]. In addition, it has 
also been shown that lateral induction functions as a system for control of the directionality in 
Delta-Notch signalling [21–23]. In this way, Serrate1 is regulated by Notch-mediated lateral 
induction in supporting cells during development of the inner ear in vertebrates [24]. Additionally, 
a theoretical model has also been developed where-by it was demonstrated that lateral induction is 
involved in the control of epidermal stem cell niches [25]. 
 
The lateral inhibition is based on the ability of the Notch pathway to amplify small differences 
in the capacity of Notch signal transmission between different cells. These models suggest that 
small differences in the activity of the Notch pathway in distinct cells may have an influence on 
the level of expression of their ligands and/or receptors, inducing autoregulation loops that 
generate a "snowball" effect. In the lateral inhibition model one cell gradually loses the expression 
of Notch receptors until eventually it carries only Notch ligands (this cell becomes the signal-
sending cell), while the other cell gradually loses the expression of Notch ligands until it 
eventually carries only receptors (this other cell becomes the signal-receiving cell). The gonadal 
development in C. elegans is a good example of lateral inhibition. The receptor activates its own 
expression and inhibits the expression of the ligand in the signal-receiving cell. 
 
The Notch signal also acquires directionality by asymmetric cell division. In this case, the 
direction of Notch signalling is determined by the asymmetrical distribution during cell division of 
a number of factors that influence Notch activity in daughter cells. The mother cell has located 
these factors at one of its poles instead of displaying a homogeneous distribution of such factors. 
One of the factors capable of modifying the Notch signal is Numb, a protein that binds Notch 
directly to avoid Notch activation. Therefore, although these two cells are competent for Notch 
signalling since both express ligands and receptors, only the cell without Numb protein expression 
will be able to receive the signal via Notch, while the other cell with Numb will send the signal.  
 
Finally, another mechanism to achieve directionality of Notch signalling is controlling the 
ligand and receptor activities through post-translational modifications. As has previously been 
depicted, the ubiquitin-dependent endocytosis of both Notch receptor and ligands has important 
consequences for their activity and, therefore, for the modulation of Notch pathway activity. In 
mammals, two ubiquitin ligases called Mindbomb and Neuralized are capable of ubiquitinating the 
Notch ligands and thus triggering their endocytosis. As a result of their action, Mind-bomb and 
Neuralized enhance the ligand capacity to activate the Notch signalling in the surrounding cells. 
Additionally, Notch activity can be controlled through glycosylation of its EGF-like repeats by 
glycosyl-transferases such as fringe in Drosophila and its counterparts in vertebrates. Distinct 
spatial patterns of expression of these proteins during embryonic development can generate the 
directionality of the Notch signalling, giving rise to different cell groups in the organism [20]. 
The two faces of Notch in cancer 
Deregulated expression of wild-type Notch receptors, ligands and target genes is observed in a 
growing number of solid and haematological tumours. Mutations in Notch receptors have also 
shown tumorigenic properties in preclinical models [3]. 
 
However, evidence shows that the Notch signaling pathway has apparently opposite functions 
in tumour development, where it may act either as an oncogene or as a tumour suppressor, 
depending on the cell context. In fact, it seems that the result of alteration in Notch signalling is 
de-pendent on its normal function in a given tissue. In this set-ting, Notch may act as an oncogene 
in those tissues where it is involved in stem cell self-renewal or in cell fate decisions. In contrast, 
Notch signalling may have a tumour suppressor role in those tissues in which Notch promotes 
terminal differentiation events (reviewed in [3]). Therefore, with the possible exception of 
keratinocyte-derived tumours, where Notch would have a tumour suppressor role, Notch signalling 
inhibition may be an effective strategy for the treatment of certain solid and haematological 
tumours (reviewed in [26–28]). 
Oncogenic role of Notch 
Breast cancer 
Because mammary glands undergo most of their development after birth and show great 
plasticity during a woman’s life, adult stem cells play a pivotal role in the biology of the mammary 
gland [29]. Notch signalling is involved in mammary stem cell self-renewal [30, 31]. In fact, 
induction of Notch signalling promotes self-renewal of mammary stem cells and branching 
morphogenesis and these effects are blocked by an anti-Notch antibody or a gamma-secretase 
inhibitor [30, 31]. 
 
Recently, it has been suggested that residual breast tumours after conventional chemotherapy 
are enriched with CSCs with increased self-renewal capability due to the alteration of 
developmental conserved signalling pathways such as Notch [32]. Accordingly, in preclinical 
models Notch signalling protects breast tumours from drug-induced apoptosis [33]. 
 
Activation of Notch signalling occurs in approximately 40% of human breast tumours. In fact, 
NOTCH1 and NOTCH2 expression have been associated with clinical outcome. It seems that 
NOTCH1 may have tumour-promoting functions, whereas NOTCH2 could play a tumour-
suppressive role [34]. Parr and co-workers showed that NOTCH1 expression was low in well-
differentiated breast tumours and was increased in poorly differentiated breast tumours, whereas 
NOTCH2 expression was high in well-differentiated breast tumours and reduced in poorly 
differentiated breast tumours [34]. These authors suggested that high NOTCH1 levels may be 
associated with a poor prognosis while high NOTCH2 levels may be associated with a higher 
overall survival [34]. Further evidence showed that high JAG1 or N1 levels in breast cancer were 
associated with poor overall survival. Furthermore, a synergistic effect of high levels of co-
expression of JAG1 and NOTCH1 on overall survival has also been shown [35]. 
 
Additionally, the loss of negative regulators of Notch signalling has been shown in breast 
cancer. In fact, NUMB-mediated negative control of Notch signalling is lost in 50% of human 
breast tumours due to specific NUMB ubiquitination and proteosomal degradation [36]. 
Furthermore, NUMB-defective breast tumours display poor prognosis [37]. Recently, Colaluca 
and co-worker shave shown that loss of NUMB protein in primary breast tumour cells causes an 
increase in Notch signalling, a de-crease in p53 levels and an increase in cell chemoresistance[37].  
Additionally, it has been suggested that NOTCH1 may mediate the tumorigenic effect of 
oncogenic RAS[38].Currently, it is well established that gain of function mutations in RAS occurs 
in early breast cancer and plays a central role in breast tumorigenesis. Weijzen and colleagues 
showed that NOTCH1 was highly expressed in all RAS-positive breast cancer samples. 
Downregulation of NOTCH1 expression in RAS-transformed human breast cells led to a 
significant decrease in their proliferation. Additionally, the inhibition of RAS signalling also led to 
the blockade of NOTCH1 activation. Furthermore, the expression of oncogenic RAS also led to 
higher levels of proteins involved in NOTCH activation [38]. 
 
A role for Notch signalling in the different breast cancer molecular subtypes has been 
suggested based on pre-clinical data and Notch signalling component expression in samples from 
breast cancer patients. Recently, Rizzo and co-workers showed cross-talk between Notch 
signalling and oestrogen receptor (ER) signalling in ER-positive breast cancer models, while 
oestradiol inhibited Notch activation in breast cancer cell lines with ER protein levels. However, 
anti-oestrogen therapy with tamoxifen blocked this inhibitory effect and reactivated Notch activity 
in these cells. Additionally, Notch inhibition enhanced the anti-tumour effects of tamoxifen in vivo 
over ER-positive breast cancer models. Finally, these authors suggested that Notch signalling 
could represent another potential therapeutic tar-get in ER-positive breast cancer (the most 
common breast cancer molecular subtype). They also showed preclinical data that supported that 
the combinations of anti-oestrogen drugs and Notch inhibitors may be more effective than an-ti-
oestrogen drugs in monotherapy in this breast cancer molecular subtype [39]. Additionally, the 
same authors, in another recent article, also showed how ERBB2 over expression suppressed 
NOTCH1 activity in ERBB2-positivebreast cancer models and how this effect could be reversed 
by trastuzumab (Trastuzumab is an anti-HER2 inhibitor that is consider the first choice of 
treatment for ERBB2-positive breast tumors). Notch inhibition also showed an anti-tumour effect 
in ERBB2-positive breast cancer models that were trastuzumab resistant. These results suggested 
that Notch might play a role in the resistance to trastuzumab in the ERBB2-positive breast cancer 
molecular subtype. This resistance may be prevented or reversed by the concomitant or subsequent 
inhibition of the Notch pathway[40]. Finally, a clearer role for Notch signalling in triple negative 
breast cancer has also been shown in pre-clinical models. These data suggest that therapeutic 
targeting of this pathway may be explored in breast cancer patients with this molecular subtype 
[41]. 
 
Based on the above evidence that supports a role for the Notch signalling pathway in breast 
cancer molecular sub-types, two phase I/II clinical trials with the gamma-secretase inhibitor MK-
0752 (Merck) in breast cancer patients are underway. These trials will determine the 
safety/tolerability and efficacy of the MK-0752 inhibitor in monotherapy or combined with 
docetaxel in locally advanced or metastatic breast cancer patients [42, 43]. In the former tri-al, 
continuous dosing of MK-0752 at 450 mg daily in patients with breast cancer is associated with 
significant toxicity, predominantly fatigue [42]. Currently, an intermittent dosing schedule is being 
explored. In the latter trial, developed by the Stem Cell Clinical Consortium, tumour samples will 
be taken from some patients who have tumours that can be easily biopsied. The samples will be 
used to test if "breast CSCs" are killed by the combination of docetaxel and MK-0752 [43]. 
Gastrointestinal tumours 
The epithelium of the small intestine is organised into finger-like villi and adjacent 
invaginations called crypts of Lieberkühn. The colon lacks villi and has a flat surface epithelium. 
In the small intestine, the crypt compartment contains the stem cells and the progenitors, whereas 
the villus compartment is made up entirely of differentiated cells (re-viewed by [44]). The stem 
cells of the bottom of the crypt give rise to the transit amplifying cells, which divide robustly 
before terminal differentiation into one of the four principle cell types: adsorptive enterocytes, 
mucus-secreting goblet cells, hormone-secreting enteroendocrine cells, and lysozyme- and 
cryptidin-producing Paneth cells [44]. 
 
The self-renewal of the intestine is regulated by highly evolutionary conserved signalling 
pathways, which include the BMP, Hh, Notch and Wnt [45].  
Multiple proteins belonging to the Notch signalling pathway are expressed in the intestinal 
crypts and several Notch target genes are involved in the control of the intestine self-renewal such 
as Hes1 and Math1 (the latter gene, a target of Hes1-mediated gene repression) (reviewed in[44]). 
The Notch signalling pathway is required to establish the fate of differentiating cells exiting from 
the transit-amplifying compartment. Notch has also been shown to have an essential role within 
the crypt compartment to maintain crypt progenitors in an undifferentiated, proliferative state 
(reviewed in [44]). 
 
Cross-talk between Wnt and Notch intracellular path-ways has also been suggested by van Es 
and coworkers. Notch might be acting downstream on Wnt in the intestine self-renewal and in the 
promotion of proliferation in adenomas and adenocarcinomas of the intestine [46]. 
 
Disruption of Notch signalling in colon cancer cell lines by gamma-secretase inhibitors 
induced apoptosis [47,48]. Furthermore, it has been shown that the pre-treatment of these cell lines 
with gamma-secretase inhibitors enhances oxaliplatin effects [47] and also enhances the action of 
taxanes [48]. 
 
Additional evidence indicates that the Notch signalling pathway may be associated with 
chemotherapy resistance in gastric tumours [48, 49]. Oxaliplatin-resistant gastric cancer cell lines 
showed increased levels of VEGF and the NOTCH ligands JAG1 and DLL4, associated with a 
higher angiogenic rate [49]. 
Haematological tumours: T-cell lymphoblastic leukaemia/lymphoma 
Notch signalling has an important role in haematopoiesisas a mediator of cell fate 
determination and in the self-renewal of haematopoietic stem cells [50]. 
 
The Notch signalling pathway also plays a central role in T-cell acute lymphoblastic 
leukaemia/lymphoma (T-ALL) pathogenesis. Less than 1% of T-ALL show a chromosome 
translocation [42, 47] that leads to the expression of constitutively active Notch1 (N1ICD). 
Additionally, more than 50% of human T-ALLs without specific [42, 47] chromosome 
translocation show activating mutations inNotch-1([51], reviewed in [52]). Based on these 
findings, a safety/efficacy phase I clinical trial with the gamma-secretase inhibitor MK-0752 in 
patients with refractory T-ALL was developed by Merck [53]. 
Tumour suppressor role 
Keratinocyte-derived carcinoma  
Notch1-mediated signalling in the epidermis promotes the commitment of stem cells toward 
transit populations of cells that are still actively proliferating, although only for a limited time until 
they differentiate [54]. Thus, the function of Notch1 in this tissue is to induce terminal 
differentiation processes. Notch1 in primary mouse keratinocytes has shown a tumour suppressive 
role. Notch1 promotes the withdraw-al of proliferating primary keratinocytes from the cell cycle 
and their entrance into differentiation [55, 56]. Conditional deletion of the Notch1gene in the 
epidermis of mouse models results in epidermal hyperplasia and development of spontaneous 
basal cell carcinoma-like tumours and facilitation of chemical-induced skin carcinogenesis (re-
viewed in [3]). 
 
The tumour suppressor effect of Notch1 in murine skin appears to be mediated by the 
repression of signalling pathways implicated in self-renewal of skin stem cells such as Hh and Wnt 
[56–58]. 
  
According to the tumour suppressor role of Notch in mouse skin, human basal cell carcinomas 
show reduced Notch1, Notch2 and JAG1 expression [57]. Furthermore, basal cell carcinoma is 
frequently associated with higher Hh signalling. Consistent with these data, Notch1deletionin 
mouse epidermis leads to aberrant expression of Gli2, a downstream component of the Hh 
cascade. Therefore, loss of Notch1 in human epidermis may be contributing, as well as aberrant 
Hh signalling, to the development of basal cell carcinomas [3].  
 
Epidermal growth factor receptor (EGFR) signalling is associated with skin cancer. 
Accordingly with the tumour suppressor role of Notch1 in the skin, EGFR has been shown as a 
negative regulator of Notch1transcription in keratinocytes [59]. 
 
Increased Wnt signalling is also associated with the maintenance of stem cell compartments in 
the skin and with keratinocyte-derived malignancies. Wnt signalling, as well as Hh signalling, is 
suppressed by Notch-1 activation and is elevated in keratinocytes and tumours as a consequence of 
loss of Notch1 function [56]. 
Conclusions 
The hypothesis that cancers may arise from CSCs, which share the self-renewal feature of 
normal stem cells, has changed the perspective on new approaches to treating the disease such as 
CSC target therapies. 
 
Developmental signalling pathways such as Notch, BMPs, Wnt and Hh play critical roles in 
controlling adult stem cells in homeostatic tissues. Alterations in the components of these 
pathways have also been associated with cancer. In fact, the Notch signalling pathway is a highly 
evolutionary conserved signalling pathway involved in proliferation and differentiation of 
embryonic and adult stem cells and also seems to be involved in cancer development. If we take 
into account the above information, it seems reasonable to consider these signalling pathway 
components as good targets for the development of new anticancer drugs. 
 
Currently, five clinical trials with the gamma secretase inhibitor MK-0752 from Merck are 
underway in cancer patients (breast cancer, central nervous system cancer and leukaemia and 
lymphoma patients). Furthermore, other pharmaceutical companies are also working on the 
development of drugs against the Notch pathway. They are not only focusing on obtaining new 
gamma secretase inhibitors capable of simultaneously blocking all Notch isoforms, they are also 
looking for monoclonal antibodies against specific Notch receptors and ligands to reduce the 
treatment-associated toxicities. 
 
Further, clinical trials with these new anti-Notch agents in combination with current anti-
cancer therapies are necessary to provide proof of concept of their activity over CSC in a specific 
tumour type. 
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